The effect of phytosterols on quality of life in the treatment of benign prostatic hyperplasia

Pharmacotherapy

Volumn 22, Issue 11, 2002, Pages 1426-1432

  Coleman, Craig I ^a   Hebert, John H ^b   Reddy, Prabashni ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ABT ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AZUPROSTAT; CAMPESTEROL; DOXAZOSIN; FINASTERIDE; FLAVONOID; HERBACEOUS AGENT; NON PRESCRIPTION DRUG; PHYTOSTEROL; PLACEBO; PLANT EXTRACT; SABAL EXTRACT; SITOSTEROL; STIGMASTEROL; TERAZOSIN;

BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; HYPOXIS; INSTRUMENT; MALE; MEDICAL SOCIETY; NOCTURIA; PHYTOTHERAPY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SABAL; SAMPLE SIZE; SCORING SYSTEM; SYMPTOM; TECHNIQUE; TREATMENT OUTCOME; UNITED STATES; URINE FLOW RATE;

CLINICAL TRIALS; HUMANS; MALE; PHYTOSTEROLS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE;

EID: 0036843911     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.16.1426.33695     Document Type: Review

References (35)

1. Witt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 1998;280:1604-9.
2. Blumenthal M, ed. The Complete German Commission E Monographs. Boston: American Botanical Council, 1998.
3. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002;12:15-18.
4. Wilt TJ, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2;2002.
5. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urol 2001;58(suppl 6A):25-32.
6. Leidy NK, Revicki DA, Geneste G. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113-27.
7. Harnack LJ, Rydell SA, Stang J. Prevalence of use of herbal products by adults in the Minneapolis/St. Paul, Minn., metropolitan area. Mayo Clin Proc 2001;76:688-94.
8. Miller LG, Hume A, Harris M, et al. White paper on herbal products. Pharmacotherapy 2000;20:877-91.
9. Rhodes PR, Kroogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urol 1999;53:1090-8.
10. De la Rosette J, Alivizatos G, Madersbacher S, et al. EAU guidelines on benign prostatic hyperplasia. Eur Urol 2001;40:256-63.
11. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998;160:1358-67.
12. Boyle P, Altwein JE, Bartsch G. Patients' perception of the effect of medical therapy for benign prostatic hypertrophy in the PREDICT trial [abstr]. J Urol 1999;161(suppl 266):A1029.
13. Batista-Miranda JE, De la Cruz Diez M, Arano Bertran P, Villavicencio H. Quality-of-life assessment in patients with benign prostatic hyperplasia. Effects of various interventions. Pharmacoeconomics 2001;19:1079-90.
14. Dickerson K, Scherer R, Lefebvre C. Systematic reviews: Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
15. Cockett ATK, Khoury S, Aso Y, eds. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, UK: SCI Ltd., 1993.
16. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
17. Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd Ed. New York: Lippincott Williams & Wilkins, 1996:41-8.
18. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire - New outcome measure for primary care. BMJ 1992;305:160-4.
19. Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc 1991;39:378-82.
20. The EuroQol Group. EurQol - A new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
21. Donovan JL, Kay HE, Peters TJ, et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-BPH study. Br J Urol 1997;80:712-21.
22. Lukacs B, Comet D, Grange JC, Thibault P. Construction and validation of a short from benign prostatic hypertrophy health related quality of life questionnaire. Br J Urol 1997;80:722-30.
23. Barry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease specific health status in men with benign prostatic hyperplasia. Med Care 1995;33(suppl A):S145-55.
24. Epstein RS, Deverka PA, Chute CG, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992;45:1431-5.
25. Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study. Curr Ther Res 1994;55:776-85.
26. Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: A double-blind comparison of two dosage regimens. Adv Ther 1999;15:231-9.
27. Carro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate 1996;29:231-40.
28. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58:960-5.
29. Berges RR, Windler J, Trampisch HJ, Senge TH. Randomized, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995;345:1529-32.
30. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with β-sitosterol: An 18-month follow-up. Br J Urol Int 2000;85:842-6.
31. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of β-sitosterol (phytosterol) for treatment of benign prostatic hyperplasia. Br J Urol 1997;80:427-32.
32. Blendon RJ, DesRoches CM, Benson JM, Brodies M, Altman DE. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 2001;161:805-10.
33. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA 1998;280:1569-75.
34. O'Hara M, Kiefer D, Farrel K, Kemper K. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998;7:523-36.
35. Hays RD, Woolley JM. The concepts of clinically meaningful differences in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000;18:419-23.